ID
25661
Beschrijving
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease. Study part: Randomization/Drug dispensing
Trefwoorden
Versies (4)
- 12/08/17 12/08/17 -
- 12/08/17 12/08/17 -
- 12/08/17 12/08/17 -
- 08/09/17 08/09/17 -
Geüploaded op
8 settembre 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Randomization/Drug dispensing GSK study Dyskinesia in Parkinson's disease NCT00363727
Randomization/Drug dispensing study Dyskinesia in Parkinson's disease NCT00363727
Similar models
Randomization/Drug dispensing study Dyskinesia in Parkinson's disease NCT00363727
C0678257 (UMLS CUI [1,2])
C2348070 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])